anoth cf triplerx approv acceler sale
total cf sale million billion beat estim
street consensu driven orkambi uptak children expect continu symdeko
launch grow cf sale billion in-lin manag guidanc
billion tax expens impact hit bottom line non-gaap dilut ep
estim await phase triplerx
read-out quarter reacceler sale profit partner crispr
commenc beta-thalassemia sickl cell diseas studi first-in-man
data year vertex end cash billion reiter overweight
rate vertex inch price target
strong cf sale increas forecast total cf sale million
total billion beat estim street consensu
beat driven increas orkambi sale million pediatr uptak
howev expect symdeko continu cannib orkambi adult
switch forecast declin orkambi billion
billion symdeko sale came slightli consensu
million million first full year launch approv europ
market symkevi expect sale grow billion
kalydeco sale million billion year project flat
vertex provid new cf sale guidanc billion
increas forecast billion billion model cf sale
sequenti declin million due inventori stock higher gross-
to-net discount quarter
tax payment temper profit cf sale growth non-gaap
oper profit margin expans manag guid non-
tax rate beyond vertex record non-cash benefit
incom tax billion make tax payment previous accumul
nol estim non-gaap dilut ep slightli
due tax impact
continu page
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
price close februari
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
triplerx reacceler sale profit despit temper profit
believ approv vertex triplerx treat cf patient drive
sale bottom line vertex report posit efficaci safeti
data two pivot phase triplerx trial next-gen corrector symdeko
homozyg het/min cf patient last year het/min trial show mean
absolut improv baselin week vs placebo
trial show benefit baselin versu placebo
vertex report top-lin data parallel phase triplerx trial next-gen
corrector quarter vertex intend file nda best triplerx regimen
approv around earli vertex also initi triplerx studi
children age year homozyg heterozyg
mutat project triplerx grow total cf sale billion drive non-gaap
dilut ep
crispr data vertex also crispr crsp
overweight co-develop six therapi includ cystic fibrosi
crispr enrol first transfusion-depend beta-thalassemia patient phase
i/ii studi germani phase i/ii studi underway scd
fda recent grant track design scd first-in-man data
expect year vertex also develop three intern develop program
pain antitrypsin focal segment glomerulosclerosi fsg
inhibitor report phase iib acut pain data first
corrector clinic first fsg candid enter clinic year
invest recommend reiter overweight rate inch price target
revis estim roll forward discount period appli
price-to-earnings multipl non-gaap dilut ep prior appli multipl
non-gaap dilut ep discount back lower non-
dilut ep primarili due higher project non- tax rate return
multipl multipl base high confid triplerx phase data quarter
subsequ sale earn estim roll
price-to-earnings multipl discount period
rate crsp feb close overweight price target base proj ev
net cash risk technolog unproven may fail man
crispr involv patent litig could advers effect compani abil conduct
busi compani like requir futur capit
page
thousand except per share data
good sold
royalti payment
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
